First Federal Pradaxa MDL Conference Scheduled

In an initial status conference set for early October, the judge recently appointed to preside over federal Pradaxa lawsuit litigation in an MDL will meet with lawyers involved in these cases.

A Pradaxa MDL was established by the U.S. Judicial Panel on Multidistrict Litigation on August 8, consolidating federal dangerous drug lawsuits filed throughout the nation by individuals who have suffered from uncontrolled Pradaxa internal bleeding, or who have lost loved ones to Pradaxa side effects.

All of the lawsuits are based on similar claims that Boehringer Ingelheim, the maker of Pradaxa, did not provide sufficient warning to patients and doctors about the potential for serious injury or death as a result of internal bleeding that does not have an effective reversal agent.

Judge David R. Herndon of the Southern District of Illinois will preside over the coordinated pretrial proceedings.  When the MDL was established, there were 21 federal Pradaxa lawsuits in 11 states.  Now, there are nearly 80 cases that have been added to the MDL and more complaints continue to be filed.

Judge Herndon’s goal, he has stated, is to arrive at a unified case management plan upon which all counsel agrees and to keep the proceedings moving at an efficient pace.  It is estimated that the first Pradaxa trial will begin in 18 to 24 months.

“It is clear that whether the number of plaintiffs remain static or increase, the allegations that have been made are quite serious,” wrote Judge Herndon in the August 17 Order. “The plaintiffs and potential plaintiffs will benefit from an expeditious resolution to the factual allegations made in this case, whether the plaintiffs’ allegations are proven or disproven.”

Pradaxa (dabigitran) is a blood thinner prescribed to prevent strokes and heart attacks in patients with the heart condition atrial fibrillation, which makes a person more prone to blood clots.  Pradaxa was highly promoted as a better alternative to warfarin (Coumadin), but there is no current reversal agent for Pradaxa bleeding, and a warfarin bleed may be stopped with a timely dose of Vitamin K.

The Institute for Safe Medication Practices (ISMP) analyzed all Pradaxa adverse event reports received by the FDA in 2011 and reported on their findings earlier this year.  Researchers found that there were 2,367 reports of serious Pradaxa internal bleeding and 542 reports of Pradaxa deaths.  Warfarin was only associated with 1,106 adverse event reports and 72 deaths.


Contact a Pradaxa Lawyer

If you have suffered or lost a loved one as a result of Pradaxa internal bleeding, you may be legally entitled to substantial compensation for your damages. To learn more about Pradaxa lawsuits and your rights, contact an experienced pharmaceutical product liability lawyer to schedule a free appointment.

Sept. 18, 2012 | Tags: Dangerous Drugs, Pradaxa

View All Legal News